Inapill

Inapill is pioneering a novel approach to inflammation by developing oral small molecules that target immunometabolism, aiming to simultaneously suppress multiple disease-driving cytokines. The company's platform is inspired by research on sex differences in inflammation and seeks to overcome the limitations of existing biologics, such as cytokine redundancy, immunogenicity, and poor patient compliance due to injectable administration. Backed by the venture studio General Inception, Inapill is in the discovery and preclinical development stage, building a team with deep expertise in immunology, metabolism, and protein biochemistry to advance its pipeline.

Platform for discovering oral small molecules that target immunometabolism to simultaneously suppress multiple pro-inflammatory cytokines by tuning mitochondrial function in immune cells.

Inapill competes in the crowded inflammation/autoimmunity space against dominant biologic drugs (e.g., Humira, Enbrel) and oral JAK inhibitors. Its differentiation lies in its novel upstream, metabolic mechanism of action and oral delivery. Competitors include larger biopharma firms and other biotechs exploring immunometabolism, though few have advanced clinical candidates.